SLC5A2 and hydrops fetalis: CV outcome trials, such as EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, and VERTIS CV, have highlighted the efficacy of SGLT2 inhibitors in reducing HF-related outcomes in individuals with T2D [4–7].